BioSpace News Archive

Until recently, the occurrence of serious fungal infections had been fairly uncommon. However, with a rapid increase in systemic infections, the global market for fungal infections is slated for tremendous progress over the next few years.

Dr. Lana Gerzenshtein, PharmD, BCPS, CSP, Manager of Network Clinical Programs at Excelera to speak at the virtual summit to share expertise on clinical outcomes initiatives and opportunities within health system-based specialty pharmacies [24-August-2020] MINNEAPOLIS , Aug. 24, 2020 /PRNewswire/ -- Excelera® , the company behind the Excelera Network, announced today

International Phase 2/3 trial in countries with high rates of coronavirus infection planned to start late 2020, pending initial Phase 1 outcome

UNION has successfully completed inhalation dosing of 44 healthy volunteers, confirming the safety and tolerability of UNI911

DUSA Pharmaceuticals, Inc., (“DUSA”), a wholly owned subsidiary of Sun Pharmaceutical Industries, Inc. (“SPII”) today announced that it has reached a resolution with the United States Department of Justice (DOJ) concerning the promotion of LEVULAN® KERASTICK® (aminolevulinic acid HCL) and BLU-U®.

NanoVibronix, Inc. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 4,333,334 shares of common stock of the Company, at a price to the public of $0.75 per share, less underwriting discounts and commissions.

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that due to public health restrictions related to the COVID-19 pandemic, its annual general meeting (the “Meeting”) will be held virtually by live webcast.